Pfizer Reports Findings in Managed Care (Risk of Mortality In Older Adults With Loss of Appetite: an Analysis of Medicare Fee-for-service Data): Managed Care

2024 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- New research on Managed Care is the subject of a report. According to news originating from New York City, New York, by NewsRx correspondents, research stated, “Prior research suggested that loss of appetite (LOA) among adults with Medicare fee -for -service (FFS) insurance in the United States increased the risk of mortality within 1 year; those findings were not adjusted for risk factors and confounders. The objective of this study was to compare the risk of mortality among Medicare FFS beneficiaries with LOA to a control group without LOA while controlling or adjusting for age, comorbidities, body mass index (BMI), and weight loss.”

Financial support for this research came from Pfizer.

Our news journalists obtained a quote from the research from Pfizer, “Retrospective and observational analysis of Medicare FFS health insurance claims data from October 1, 2015 to December 31, 2021. Claims from all settings (e.g., hospital inpatient/outpatient, office, assisted living facility, skilled nursing facility, hospice, rehabilitation facility, home) were included in these analyses. The LOA group included all individuals aged 65-115 years with continuous Medicare FFS medical coverage (Parts A and/or B) for at least 12 months before a claim with ICD-10 diagnosis code ‘R63.0 Anorexia’. The control group was drawn from individuals aged 65-115 years with continuous Medicare FFS coverage who did not have a diagnosis of R63.0. Individuals with LOA were matched 1:3 to those in the control group based on age, sex, and race/ethnicity. Mortality in the LOA group was compared to mortality in the control group using Kaplan-Meier and Cox regression analyses and stratified or adjusted in terms of Charlson Comorbidity Index (CCI), claims -based frailty index (CFI), BMI, and weight loss. The study population of 1,707,031 individuals with LOA and 5,121,093 controls without LOA was 61.7% female and 82.2% White. More individuals with LOA compared with the control group had a CCI score 5+ (52.4% vs. 19.4%), CFI score 5+ (31.6% vs. 6.4%), and BMI < 20 kg/m2 (11.2% vs. 2.1%). Median follow-up was 12 months (individuals with LOA) and 49 months (control group). In a matched population, the risk of mortality was significantly higher (unadjusted hazard ratio 4.40, 95% confidence interval 4.39-4.42) for individuals with LOA than the control group. Median survival time was 4 months (individuals with LOA) and 26 months (control group); differences in survival time remained when stratifying by CCI, BMI, and weight loss. Individuals with LOA had a substantially increased risk of death even after matching for age, sex, race/ ethnicity, and adjusting for comorbidities.”

According to the news editors, the research concluded: “These findings highlight the burden of illness in older adults with LOA and the need for therapies.”

This research has been peer-reviewed.

For more information on this research see: Risk of Mortality In Older Adults With Loss of Appetite: an Analysis of Medicare Fee-for-service Data. The journal of nutrition health & aging, 2024;28(3). The journal of nutrition health & aging can be contacted at: Springer France, 22 Rue De Palestro, Paris, 75002, France.

The news correspondents report that additional information may be obtained from Simon Dagenais, Pfizer, New York, NY, United States. Additional authors for this research include Sunday Clark, Feng Dai, Roger A. Fielding, Cera Cantu, Sapna Prasad and John D. Groarke.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jnha.2023.100035. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)